Literature DB >> 11113239

A placebo-controlled crossover trial of creatine in mitochondrial diseases.

T Klopstock1, V Querner, F Schmidt, F Gekeler, M Walter, M Hartard, M Henning, T Gasser, D Pongratz, A Straube, M Dieterich, W Müller-Felber.   

Abstract

To test the efficacy and safety of creatine (Cr) monohydrate in mitochondrial diseases, 16 patients with chronic progressive external ophthalmoplegia or mitochondrial myopathy were randomized in a crossover design to receive double-blind placebo or 20 g Cr/day for 4 weeks. Cr was well tolerated, but there were no significant effects with regard to exercise performance, eye movements, or activities of daily life. The power of this pilot study was limited and future multicenter trials are needed.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11113239     DOI： 10.1212/wnl.55.11.1748

Source DB:  PubMed          Journal:  Neurology        ISSN： 0028-3878            Impact factor:   9.910


  19 in total

Review 1.  Chronic progressive external ophthalmoplegia.

Authors:  Andrew G Lee; Paul W Brazis
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

Review 2.  Mitochondrial energetics and therapeutics.

Authors:  Douglas C Wallace; Weiwei Fan; Vincent Procaccio
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

3.  Why are there no proven therapies for genetic mitochondrial diseases?

Authors:  Peter W Stacpoole
Journal:  Mitochondrion       Date:  2011-05-13       Impact factor: 4.160

Review 4.  Creatine supplementation in health and disease: what is the evidence for long-term efficacy?

Authors:  Wim Derave; Bert O Eijnde; Peter Hespel
Journal:  Mol Cell Biochem       Date:  2003-02       Impact factor: 3.396

Review 5.  Creatine for treating muscle disorders.

Authors:  Rudolf A Kley; Mark A Tarnopolsky; Matthias Vorgerd
Journal:  Cochrane Database Syst Rev       Date:  2013-06-05

Review 6.  Pharmacokinetics of the dietary supplement creatine.

Authors:  Adam M Persky; Gayle A Brazeau; Günther Hochhaus
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

7.  Oral creatine supplementation facilitates the rehabilitation of disuse atrophy and alters the expression of muscle myogenic factors in humans.

Authors:  P Hespel; B Op't Eijnde; M Van Leemputte; B Ursø; P L Greenhaff; V Labarque; S Dymarkowski; P Van Hecke; E A Richter
Journal:  J Physiol       Date:  2001-10-15       Impact factor: 5.182

8.  A plasma signature of human mitochondrial disease revealed through metabolic profiling of spent media from cultured muscle cells.

Authors:  Oded Shaham; Nancy G Slate; Olga Goldberger; Qiuwei Xu; Arvind Ramanathan; Amanda L Souza; Clary B Clish; Katherine B Sims; Vamsi K Mootha
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-08       Impact factor: 11.205

Review 9.  How can we treat mitochondrial encephalomyopathies? Approaches to therapy.

Authors:  Rita Horvath; Grainne Gorman; Patrick F Chinnery
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

Review 10.  Review of clinical trials for mitochondrial disorders: 1997-2012.

Authors:  Douglas S Kerr
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.